Ethical challenges in stroke research

Stroke

Volumn 29, Issue 8, 1998, Pages 1725-1729

  Slyter, Howard ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Ethics, medical; Informed consent

Indexed keywords

ALTEPLASE; DEXTRORPHAN; FIBRINOLYTIC AGENT; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; PLACEBO;

ACUTE DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG TOXICITY; HUMAN; HYPOTENSION; INFORMED CONSENT; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; NAUSEA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; VERTIGO; VOMITING;

EID: 0031902189     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.8.1725     Document Type: Review

References (66)

1. Marler JR, Walker MD. Clinical research on stroke: the NINCDS strategy. In: Ginsberg, MD, Dietrich WD, eds. Cerebrovascular Diseases. New York, NY: Raven Press: 1989:17-20.
2. Clinical trials acceleration program. National Stroke Association Newsletter. 1994;11:9, 15.
3. Ginsberg MD. The validity of rodent brain-ischemia models is self-evident. Arch Neurol. 1996;53:1065-1067.
4. Zivin JA, Grotta JC. Animal stroke models: they are relevant to human disease. Stroke. 1990;21:981-983. Editorial.
5. Alves WA, Macciocchi SN. Ethical considerations in clinical neuroscience. Stroke. 1996;27:1903-1909.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
7. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke. 1997;28: 1530-1540.
8. Yatsu FM, Zivin J. Hypertension in acute ischemic strokes: not to treat. Arch Neurol. 1985;42:999-1000.
9. Spence JD, DelMaestro RF. Hypertension in acute ischemic strokes: treat. Arch Neurol. 1985;42:1000-1002.
10. Powers WJ. Acute hypertension after stroke. Neurology. 1993;43: 461-467.
11. Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, Feinberg W, Mayberg M. Guidelines for the management of patients with acute ischemic stroke. Stroke. 1994;25:1901-1914.
12. Brain Attack Coalition. Brain Attack Coalition Slide Presentation Syllabus. Englewood, Colo: National Stroke Association; 1995:53.
13. Morfis L, Schwartz RS, Poulos RP, Howes LG. Blood pressure changes in acute cerebral infarction and hemorrhage. Stroke. 1997;28:1401-1405.
14. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984;15: 413-416.
15. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:723-725.
16. Sundt TM, Smith HC, Campbell JK, Vlietstra RE, Cucchiara RF, Stanson AW. Transluminal angioplasty for basilar artery stenosis. Mayo Clin Proc. 1980;55:673-680.
17. Waltz AG. Effect of blood pressure on blood flow in ischemic and in nonischemic cerebral cortex. Neurology. 1968;18:613-621.
18. Evidente V, Yagnik P. Blood pressure management in acute stroke. Neurology. 1996;46:A256. Abstract.
19. Vorstrup S, Andersen A, Blegvad N, Paulson OB. Calcium antagonist (PY 108-068) treatment may further decrease flow in ischemic areas in acute stroke. J Cereb Blood Flow Metab. 1986;6:222-229.
20. Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JW, Molony DA, Barron BJ. Should hypertension be treated after acute stroke? Arch Neurol. 1993;50:855-862.
21. Wahlgren NG, MacMahon DG, DeKeyser J, Indredavik B, Ryman T, for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;4:204-210.
22. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J, Lifarizine Study Group. The effects of lifarizine in acute cerebral infarction: a pilot safety study. Cerebrovasc Dis. 1996;6:156-160.
23. Smith WB, Clifton GG, O'Neill WM, Wallin JD. Antihypertensive effectiveness of intravenous labetalol in accelerated hypertension. Hypertension. 1983;5:579-583.
24. Patel RV, Kertland HR, Jahns BE, Zarowitz BJ, Mlynarek ME, Fagan SC. Labetalol: response and safety in critically ill hemorrhagic stroke patients. Ann Pharmacother. 1993;27:180-181.
25. Grossman E, Messerli FH, Grodzickj T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331.
26. Ferguson RDG, Ferguson JG. The proper study of fibrinolysis is. . . . AJNR Am J Neuroradiol. 1995;16:805-807. Letter.
27. Wolpert SM, Caplan L. Comment in reply to "The proper study of fibrinolysis is. . . ." AJNR Am J Neuroradiol. 1995;16:807-808.
28. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Gent M, Driscoll RM, and the PROACT Investigators. The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT): results of 6 mg dose tier. Stroke. 1996;27:164. Abstract.
29. Clark WM, Barnwell SL, Nesbit GM. Potential role of interventional neurovascular therapy for cerebrovascular disease. The Neurologist. 1997;3:95-103.
30. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxicischemic brain damage. Ann Neurol. 1986;19:105-111.
31. Albers GW. Potential therapeutic uses of N-methyl-D-aspartate antagonists in cerebral ischemia. Clin Neuropharmacol. 1990;13:177-197.
32. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
33. Albers GW, Goldberg MP, Choi DW. N-methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia? Ann Neurol. 1989;25:398-403.
34. Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg. 1996;84:860-866.
35. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
36. Grotta JC, Picone CM, Ostrow PT, Strong RA, Earls RM, Yao LP, Rhoades HM, Dedman JR. CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol. 1990;27:612-619.
37. Albers GW, Goldberg MP, Choi DW. Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol. 1992;49:418-420.
38. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM, on behalf of the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
39. Albers GW, Atkinson R, Kelley RE, Rosenbaum DM, Katz P, Lesko LM, Paul K, Rae J, Modi M, Yoo K, Pitman V, Lehr L. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist Ro-01-6794/706 in patients with acute ischemic stroke. Bull NY Acad Sci. 1995;765:249-261.
40. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062-1072.
41. Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
42. Steinberg GK, Panahian N, Perez-Pinzon MA, Sun G, Modi MW, Sepinwall J. Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischaemia. Neurobiol Dis. 1995;2: 109-118.
43. Swan JH, Meldrum BS. Protection by NMDA antagonists against selective cell loss following transient ischaemia. J Cereb Blood Flow Metab. 1990;10:343-351.
44. Ginsberg MD. The concept of the therapeutic window: a synthesis of critical issues. In: Moskowitz MA, Caplan LR, eds. Cerebrovascular Diseases: Nineteenth Princeton Stroke Conference. Boston, Mass: Butterworth-Heinemann: 1995:331-351.
45. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA. 1990;263:65-68.
46. Lyden PD, Rapp K, Babcock T, Rothrock J. Ultra-rapid identification, triage, and enrollment of patients into clinical trials. J Stroke Cerebrovasc Dis. 1994;4:106-113.
47. Fisher M, Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. JAMA. 1993;270:360-364.
48. Office for Protection from Research Risks. Protecting Human Research Subjects: Institutional Review Board Guidebook. Washington, DC: US Government Printing Office, Superintendent of Documents, Mailstop SSOP 20402-9328: 1993. §3:1-10.
49. Muir KW, Multicenter Acute Stroke Trial-Italy. Lancet. 1996;347:391. Letter.
50. Dresser R. Mentally disabled research subjects. JAMA. 1996;276:67-72.
51. Cal Health and Safety Code §24175.
52. TD v NY State Office of Mental Health, 650 NYS 2d 173 (AD 1 Dept 1996).
53. American College of Physicians. Cognitively impaired subjects. Ann Intern Med. 1989;111:843-848.
54. Wichman A, Sandler AL. Research involving critically ill subjects in emergency circumstances: new regulations, new challenges. Neurology. 1997;48:1151-1155.
55. 61 Federal Register 192 (1996).
56. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987;17:20-24.
57. Beecher HK. Experimentation in Man. Springfield. Ill: Charles C Thomas, Publisher; 1959.
58. Spiro HM. Constraint and consent: on being a patient and a subject. N Engl J Med. 1975;293:1134-1135.
59. Pellegrino ED. Beneficence, scientific autonomy, and self-interest: ethical dilemmas in clinical research. Camb Q Healthc Ethics. 1992; 4:361-369.
60. Annas GJ. Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. J Contemp Health Law Policy. 1996;12: 297-324.
61. Office for Protection from Research Risks. Protecting Human Research Subjects: Institutional Review Board Guidebook. Washington, DC: US Government Printing Office, Superintendent of Documents, Mailstop SSOP 20402-9328; 1993. §3:42.
62. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
63. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR, for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 1996;276:961-966.
64. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
65. Davis SM, Albers GW, Diener H, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 1997,349:32.
66. Jonas H. Philosophical reflections on experimenting with human beings. Daedalus. 1969;98:219-247.